Sep 2026· Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie· 0 citations· 51 references
Medicine
TL;DR
It is suggested that the chronic use of exogenous insulin may not influence the functional or anatomic response to anti-VEGF injections in diabetic patients on chronic exogenous insulin therapy.
Abstract
Purpose
Diabetic macular edema (DME) is a leading cause of vision loss in diabetic patients worldwide. This study assessed whether there was a difference in functional and anatomic responsiveness to anti-VEGF therapy for DME among patients on chronic exogenous insulin therapy.
Methods
This was a single-center retrospective cohort study of patients diagnosed with DME between 2014 and 2022. Patients were divided into two groups: those who were treated with exogenous insulin and those who were not. Treatment characteristics such as the type and total number of anti-VEGF injections, the use of intravitreal or periocular steroids, and length of follow-up were recorded from patient charts. Functional and anatomic ocular characteristics were measured at baseline and six-month intervals up to 24 months from the time of DME diagnosis. The main outcome measures were change in best corrected visual acuity (BCVA), central foveal thickness (CFT), and macular volume (MV).
Results
101 patients (148 eyes) met the criteria for inclusion in this study. 82 patients (81.2%) used insulin while 19 patients (18.8%) did not. There were no significant differences in the stage of diabetic retinopathy, BCVA, CFT, or MV at baseline between the two groups. Patients in the no insulin group received more steroid injections in the first 12 months of treatment (0.8 vs. 0.2, p = 0.003); however, there were no significant differences in final BCVA, CFT, or MV between groups after 24 months (p > 0.05).
Conclusion
The results of this study suggest that the chronic use of exogenous insulin may not influence the functional or anatomic response to anti-VEGF injections.
This narrative critical review examines the effectiveness of intravitreal vascular endothelial growth factor (VEGF) inhibition and the clinical, structural, and treatment-related characteristics associated with visual and anatomical response.
G. Martines, G. Chiesa, José Henrique Casemiro et al.· International Health Science...· 0 citations
Objective: To compare the anti-VEGF therapy and corticosteroids in improving best-corrected visual acuity (BCVA) and
reducing central macular thickness (CMT) in UME patients.
Study design and Setting: A Prospective Cohort Study conducted at Sindh Institute of Ophthalmology and Vision Sciences,
Hyderabad
Methodology: In...
Sandeep Kumar, F. Wali, A. Majeed et al.· Journal of Bahria University...· 0 citations
Sustained suppression of VEGF-A is sufficient to effectively treat DME in the vast majority of patients, but edema resolution may be slow in some patients giving the false impression of poor response to anti-VEGF-A treatment.
Zainab Rustam, A. Khanani, Ohidul Mojumder et al.· American journal of ophthalm...· 0 citations
AIM
To evaluate the long-term outcomes of anti-vascular endothelial growth factor (VEGF) therapy during cataract surgery in eyes with diabetic macular edema (DME).
METHODS
This was a retrospective clinical study. Patients with DME scheduled for cataract surgery were included. Prior to surgery, DME was considered adeq...
Xi Chen, Ai-Ai Dai, Tao-Ran Zhang et al.· International Journal of Oph...· 0 citations
INTRODUCTION
Diabetic macular edema (DME) is a major cause of vision loss among working‑age adults in the United States. Currently, intravitreal anti-vascular endothelial growth factor (anti‑VEGF) injections are the first‑line pharmacological treatment for the management of center‑involving DME. However, real‑world out...
Charles Zhang, Sinan Ersan, Abdullah Virk et al.· Expert Opinion on Emerging D...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.